Endocrine Abstracts

Introduction: PCSK-9 (proprotein convertase subtilisin/kexin type 9) inhibitors are monoclonal antibodies that affect metabolism of low-density lipoprotein (LDL) by binding to the LDL receptor and promoting lysosomal degradation. There are two pcsk-9 inhibitors currently available: alirocumab (Praulent) and evolocumab (Repatha) which are administered subcutaneously every 14 days. Two large randomized studies (FOURIER, ODYSSEY) have shown that pcsk-9 inhibitors reduce LDL-chole...

Aim: Dopamine agonist (DA) therapy is recommended as first-line treatment for prolactinomas, albeit with long treatment duration and high recurrence rate after treatment withdrawal. The aim of this retrospective study was to evaluate predictors for successful DA withdrawal.Methods: The study included 59 prolactinoma patients (39 female, 20 male; age 34 (18–82) years) that were treated with DA (35.6% on cabergoline); the duration of treatment was 71 ...